Diabetes Mellitus Increases Lymph Node Metastasis Risk in Gastric Cancer: 15-Year Study Results

0
0
0

Diabetes Mellitus Increases Lymph Node Metastasis Risk in Gastric Cancer: 15-Year Study Results

Gastric cancer (GC) ranks as the fifth most common cancer and fourth leading cause of cancer death globally, with over 1 million new cases and 783,000 deaths reported annually. Meanwhile, diabetes mellitus (DM)—a chronic condition affecting more than 463 million people worldwide—has long been linked to higher cancer risk and worse outcomes. But does diabetes specifically drive the spread of gastric cancer to lymph nodes (LNs), a key step in disease progression?

A 15-year study from Nanfang Hospital, Southern Medical University, in Guangzhou, China, set out to answer that question. The findings, published in Chinese Medical Journal, suggest diabetes is an independent risk factor for more aggressive lymph node metastasis in gastric cancer patients—with implications for how doctors diagnose and treat this high-risk group.

What the Study Looked At

Lymph node metastasis is the most common way gastric cancer spreads and a critical predictor of survival. Doctors use two systems to assess LN involvement:

  • N3 stations: Lymph nodes far from the primary tumor (measuring spread distance).
  • N3b status: 15 or more metastatic LNs (measuring burden).

The research team, led by Xinhua Chen and Jiang Yu, wanted to see if diabetes worsened either measure. They analyzed data from 2,142 gastric cancer patients who underwent surgery between 2004 and 2019, excluding those with fewer than 16 examined LNs (to ensure accurate LN status) or pre-op chemotherapy/radiation. Patients were split into two groups: 1,993 without diabetes and 149 with diabetes.

How the Study Was Done

The study used a prospectively maintained database (updated in real time with patient records) to ensure data quality. Diabetes was diagnosed using standard criteria: fasting blood glucose ≥126 mg/dL, 2-hour post-oral glucose test ≥200 mg/dL, random glucose ≥200 mg/dL with symptoms, or a history of well-managed diabetes.

Lymph node status was evaluated using two gold-standard systems:

  1. Japanese Classification of Gastric Carcinoma (JCGC): Tracks where LNs are affected (e.g., stations 12–14, far from the tumor).
  2. Union for International Cancer Control (UICC-TNM): Counts how many LNs are metastatic (N3b = ≥15).

Key Findings

The results were clear: diabetes was tied to more extensive and burdensome lymph node metastasis.

  1. Wider Spread (N3 Stations):

    • 26.8% of diabetic patients had LNs affected in distant stations, vs. 19.3% of non-diabetic patients (P = 0.026).

  2. Higher Burden (N3b Status):

    • 18.8% of diabetic patients had 15+ metastatic LNs, vs. 12.8% of non-diabetic patients (P = 0.039).

  3. Independent Risk Factor:
    Even after adjusting for other variables (age, tumor size, lymphatic invasion), diabetes remained an independent predictor of both N3 stations (OR = 1.771) and N3b status (OR = 1.752).

  4. Worse Outcomes with Advanced Tumors:
    The gap between diabetic and non-diabetic patients grew as tumors deepened:

    • For stage T4b (tumor invades adjacent organs), 50% of diabetic patients had N3 stations vs. 36.6% of non-diabetic patients.
    • For T4b tumors, 44% of diabetic patients had N3b status vs. 28% of non-diabetic patients.

  5. More Examined LNs = Clearer Risk:
    When doctors checked 45+ LNs (the most accurate way to assess metastasis), diabetic patients were 2x more likely to have N3 stations and had 3.5x more metastatic LNs than non-diabetic patients.

Why This Matters

Lymph node metastasis is a “gateway” for gastric cancer to spread systemically—and diabetes may accelerate this process through several mechanisms:

  • Hyperglycemia: High blood sugar fuels tumor growth and impairs the immune system, allowing cancer cells to escape to LNs.
  • Hyperinsulinemia: Excess insulin activates pathways that drive tumor migration.
  • Tumor Suppressor Loss: A 2018 Nature study found sustained high glucose destabilizes TET2, a tumor suppressor that regulates DNA methylation—linking diabetes directly to cancer progression.

For patients, the takeaway is clear: if you have diabetes and gastric cancer, your risk of aggressive LN metastasis is higher. For doctors, this means closer monitoring of LN status in diabetic patients and potentially more aggressive treatments (e.g., adjuvant chemotherapy) to target spread.

Limitations to Consider

The study had a few caveats:

  • It was retrospective, meaning data was analyzed after the fact (though the database was prospective).
  • There were small imbalances in age (diabetic patients were older) and sex (more males in the DM group).
  • Researchers didn’t track the size of metastatic LNs, which could add another layer to understanding burden.

Takeaways for Patients and Doctors

  • Patients with diabetes: If you’re diagnosed with gastric cancer, ask your doctor about thorough lymph node evaluation (aim for 45+ examined LNs).
  • Doctors: Consider diabetes a red flag for higher LN metastasis risk. Tailor treatments—like adjuvant chemotherapy—to address this risk.

Conclusion

This 15-year study provides strong evidence that diabetes mellitus is an independent risk factor for more extensive and burdensome lymph node metastasis in gastric cancer. The findings highlight the need for personalized care for diabetic patients with GC—and underscore the importance of researching how diabetes interacts with cancer at the molecular level.

Original study: Chen X, Chen Y, Li T, et al. Diabetes mellitus promoted lymph node metastasis in gastric cancer: a 15-year single-institution experience. Chinese Medical Journal. 2022;135(8):950–961. doi:10.1097/CM9.0000000000001795
DOI: doi.org/10.1097/CM9.0000000000001795

Was this helpful?

0 / 0